Division of Medical Biochemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Cape Town, South Africa.
Biol Chem. 2011 Nov;392(11):1003-10. doi: 10.1515/BC.2011.165.
Matrix metalloproteinases (MMPs) cleave and degrade most components of the extracellular matrix, and unregulated MMP activity has been correlated to cancer and metastasis. Hence there is a burgeoning need to develop inhibitors that bind selectively to structurally similar MMPs. The inhibition profiles of peptidomimetics containing C(α) substituents at the α,β unsaturated carbon were evaluated against the recombinant forms of ADAM17, MMP1, and MMP9. The dicarboxylic acid D2 and hydroxamate C2 inhibited MMP9 but not MMP1. The unsaturated compound E2 displayed selective inhibition for MMP1, compared with the saturated precursor C2, with an IC(50) value of 3.91 μm. The molecular basis for this selectivity was further investigated by the molecular docking of E2 and D2 into the active sites of MMP1 and MMP9. These data demonstrate hydrogen-bonding interactions between the carbonyl group of the C(α) substituent of E2 and the side chain of Asn180 present in the active site of MMP1. Conversely, the docked MMP9-D2 structure shows hydrophobic and hydrogen bonding between the ligand's morpholine substituent and second carboxylic acid group with Leu187 and an amide, respectively. This study suggests that substituents other than P(1)' and P(2)' may confer selectivity among MMPs and may aid in the search for novel lead compounds.
基质金属蛋白酶(MMPs)可切割和降解细胞外基质的大多数成分,并且不受调节的 MMP 活性与癌症和转移有关。因此,迫切需要开发选择性结合结构相似的 MMP 的抑制剂。对含有 C(α)取代基的α,β-不饱和碳的肽模拟物的抑制谱进行了评估,这些取代基针对重组形式的 ADAM17、MMP1 和 MMP9。二羧酸 D2 和羟肟酸 C2 抑制 MMP9,但不抑制 MMP1。与饱和前体 C2 相比,不饱和化合物 E2 对 MMP1 表现出选择性抑制,IC(50)值为 3.91 μm。通过将 E2 和 D2 分子对接入 MMP1 和 MMP9 的活性部位,进一步研究了这种选择性的分子基础。这些数据表明,E2 的 C(α)取代基的羰基与 MMP1 活性部位中存在的 Asn180 侧链之间存在氢键相互作用。相反,对接的 MMP9-D2 结构显示配体的吗啉取代基与第二羧酸基团之间存在疏水性和氢键,分别与 Leu187 和酰胺相互作用。这项研究表明,P(1)’和 P(2)’以外的取代基可以在 MMP 之间赋予选择性,并有助于寻找新的先导化合物。